Jaguar Health Restructures Royalty Deals and Extends Debt
TipRanks (Thu, 18-Jun 8:35 PM ET)
ACCESS Newswire (Thu, 18-Jun 9:00 AM ET)
ACCESS Newswire (Fri, 12-Jun 9:00 AM ET)
Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream
Globe Newswire (Wed, 10-Jun 7:00 AM ET)
Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
Globe Newswire (Tue, 9-Jun 7:00 AM ET)
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
ACCESS Newswire (Mon, 8-Jun 4:15 PM ET)
ACCESS Newswire (Thu, 28-May 10:00 AM ET)
Jaguar Health Compliant with Nasdaq Bid Price Rule
ACCESS Newswire (Wed, 27-May 9:00 AM ET)
Jaguar Health Reports First Quarter 2026 Financials
ACCESS Newswire (Wed, 20-May 4:40 PM ET)
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Jaguar Health trades on the NASDAQ stock market under the symbol JAGX.
As of June 18, 2026, JAGX stock price declined to $2.25 with 111,234 million shares trading.
JAGX has a beta of 2.42, meaning it tends to be more sensitive to market movements. JAGX has a correlation of 0.03 to the broad based SPY ETF.
JAGX has a market cap of $1.48 million. This is considered a Sub-Micro Cap stock.
Last quarter Jaguar Health reported $20 million in Revenue and -$13.60 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $57.80.
In the last 3 years, JAGX traded as high as $37,791.48 and as low as $2.12.
JAGX has underperformed the market in the last year with a price return of -97.7% while the SPY ETF gained +26.9%. JAGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -85.5% and -26.2%, respectively, while the SPY returned +13.5% and -1.1%, respectively.
JAGX support price is $2.18 and resistance is $2.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAGX shares will trade within this expected range on the day.